期刊文献+

丙型肝炎病毒核心区多肽的抗原表位分析和原核表达

Study on the Epitopes of the Polypeptide in the Core Region of Hepatitis C Virus and its Prokaryotic Expression
原文传递
导出
摘要 目的分析HCV核心区多肽的抗原表位,选择具有优势抗原表位的多肽用原核表达载体表达,并获得该表达载体的稳定表达菌株。方法根据软件分析选取带有优势抗原表位的HCV核心区多肽,找出对应DNA序列,逆转录PCR扩增目的基因,克隆到原核表达载体中进行诱导表达。表达的目的蛋白用His Bind Columns纯化,用ELISA法检测其免疫活性。结果获得了序列正确的HCV-core基因和表达良好的该基因原核表达载体pET-28a-core,该表达载体表达的目的蛋白可被很好地纯化并具有良好的HCV抗原活性。结论成功地重组了HCV核心区蛋白,获得了HCV抗原性良好的HCV核心区抗原。 Objective To analyze the epitopes of the polypeptide in the core region of hepatitis C virus (HCV) and to select the polypeptide fragments with preponderant antigenic determinants to express in prokaryotic expression vector to obtain the strain with stable expression of the vector. Methods The polypeptide fragments in the HCV core region comprising the pre- ponderant antigenic determinants were selected by software analysis, and the corresponding DNA sequences were searched and the target genes were amplified by reverse transcription PCR. Then the gene fragment was cloned into the prokaryotic expression vector and its expression was induced. The expressed target protein was purified by His Bind Columns, and its immunocompetence was determined by ELISA. Results The HCV - core gene with right sequences and its prokaryotic expression vector with high efficiency, pET- 28a- core, were obtained. The expressed target protein could be well purified and had outstanding HCV antigenicity. Conclusions HCV core protein is successfully recomposed, and the HCV core protein with excellent HCV anti- genicity is obtained.
出处 《实用预防医学》 CAS 2013年第1期101-103,共3页 Practical Preventive Medicine
关键词 丙型肝炎病毒 抗原表位 表达 抗原性 Hepatitis C Virus Epitopes Expression Antigenicity
  • 相关文献

参考文献5

二级参考文献30

  • 1杜绍财,孙南雄,范晓峰,邱国华,尤鹏,张永祥,魏来.中国HCV5′-非编码区复合酶切分型及其3b基因型序列分析[J].中华检验医学杂志,2004,27(10):683-686. 被引量:11
  • 2戴志澄 祁国明.中国病毒性肝炎血清流行病学调查[M].科学技术文献出版社,1997.39-58.
  • 3Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol, 2003, 36:47-53.
  • 4WHO Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, antwerp, belgium. J Viral Hepat,1999, 6:35-47.
  • 5Armstrong GL, Alter MJ, MeQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of ehronle liver disease in the United States. Hepatology,2000, 31:777-782.
  • 6Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med, 1999, 341:556-562.
  • 7Lowe D, Cotton R. Hepatitis C: a review of Australia's response. Publications Production Unit, Commonwealth department of health and aged care, Commonwealth of Australia, Canberra, 1999.
  • 8Villano SA, Vlahov D, Nelson KE, et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore,Maryland. J Clin Microbiol, 1997, 35: 3274-3277.
  • 9Hollinger FB, Kirtava A, Oakley M, et al. Blood safety monitoring among patients with bleeding disorders-United States, May1998-June, 2002. MMWR, 2003,1152-1154.
  • 10Takano S, Nakamura K, Kawai S, et al. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first-and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology, 1996,23:708-712.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部